Trending...
- Webinar Announcement: Mexico's Evolving AML/CFT Environment: FATF Review and FTO Designations
- City of New Rochelle Unveils Updated GreeNR Plan, Advancing Strategies for Climate Resilience and Ad
- Hart Orthopedics: Elevating Orthopedic Care for the Long Island Community Massapequa, NY
NEW YORK, July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Agenus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 18, 2024, Agenus issued a press release "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM)." The press release stated that the "FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to survival benefit."
More on Nyenta.com
On this news, Agenus's stock price fell $10.43 per share, or 58.83%, to close at $7.30 per share on July 18, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Agenus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 18, 2024, Agenus issued a press release "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM)." The press release stated that the "FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to survival benefit."
More on Nyenta.com
- Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- HEAVY HITTERS Support Two Dog Rescues in Huntington, NY
- Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
On this news, Agenus's stock price fell $10.43 per share, or 58.83%, to close at $7.30 per share on July 18, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Mayor Evans on State of City: Rochester is moving forward with a new momentum
- Fairfield Inn by Marriott Scottsdale Old Town Opens
- Yonkers: YONKERS POLICE DEPARTMENT PARTNERS WITH WESTCHESTER COUNTY PROGRAM ASSISTING MOTORISTS ON THE AUTISM
- Passport to U.S. Customs Compliance' Series Gains Urgency Amid Escalating Tariff Turmoil
- Pelican Reef Group Announces Grand Opening of New High Point Showroom – IHFC Building H-621 & Event April 27th, 2025
- Yonkers: CITY OF YONKERS DISTRIBUTES FREE COMPOST TO YONKERS RESIDENTS
- Gotham Lab Supports E-Learning Localization for Corporate and Government Training
- MEET BOBBIE, A NEW INFLUENCER AND CREATOR MARKETING AGENCY
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing
- $TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of GB, YOTA, PORT, AKYA to Act
- Coming Up on "Financial Freedom with Tom Hegna" Financial Expert Parker Faulkner
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- Rochester: Public meetings and the solicitation of input: 2025-29 Consolidated Plan & FY 2025-26 Annual Action Plan
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gorilla Technology Group, Inc. - GRRR
- Rochester: Public Market seeks vendors for Flower City Days horticultural sales
- City of New Rochelle to Host Sustainability Community Events During Earth Week and Beyond
- SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies